Hemolytická anémie po ribavirinu – klinické poznatky a léčba

Haemolytic anemia due to ribavirin – clinical observations and treatment

This article reviews the haematological complications of the antiviral treatment of chronic hepatitis C virus infection with a combination of pegylated and nonpegylated alpha-2a and alpha-2b interferons plus ribavirin. The major side effect of combination therapy is haemolytic anemia which usually develops 4–8 weeks after initiation of treatment, and is ribavirin dose-dependent. The main risk factors of haemolytic anemia due to ribavirin in combination therapy are: higher baseline haemoglobin levels and a lower platelets count, dose of alpha-interferon administered, higher iron saturation, haptoglobin phenotype, renal function (lower baseline creatinine clearance), age (older patients are more at risk) and sex (males are more at risk). Overall risk of ribavirin-induced haemolytic anemia was 9 %. Epoetin alpha seems to be a very promising drug for the treatment of haemolytic anemia and ribavirin dose maintenance.

Key words:
haemolytic anemia, ribavirin, epoetin alpha, chronic hepatitis C.